in march 2014 , we announced that merck kgaa initiated a phase 1 dose escalation study assessing the safety , tolerability and anti-tumor activity of evofosfamide in combination with gemcitabine and nab-paclitaxel ( abraxane ® ) in patients with previously untreated , locally advanced unresectable or metastatic pancreatic adenocarcinoma . in june 2014 , we announced the initiation of a 440-patient , randomized , double-blind , placebo-controlled trial of evofosfamide in combination with pemetrexed in patients with second-line advanced non-squamous non-small cell lung cancer ( which we refer to as the 415 trial ) . the international phase 2 trial is designed to support registration and will compare the combination of evofosfamide plus pemetrexed versus the combination of pemetrexed plus placebo as second-line therapy in this patient population . the study 's primary efficacy endpoint is overall survival and secondary endpoints include safety and assessment of anti-tumor activity as determined by progression-free survival and objective response rate . 54 in march 2012 , we initiated a phase 1/2 open label clinical trial of evofosfamide to determine the maximum tolerated dose , dose limiting toxicity , safety , tolerability , clinical activity , and pharmacokinetics of evofosfamide in patients with relapsed/refractory multiple myeloma ( which we refer to as the 408 trial ) . updated results were reported at the june 2014 asco annual meeting showing initial signs of clinical activity of the combination of evofosfamide and low dose dexamethasone in patients with extensively treated relapsed/refractory multiple myeloma . in july 2014 , we announced the initiation of dosing in the final stage of the 408 trial , which is evaluating evofosfamide in combination with the proteasome inhibitor bortezomib ( velcade ® ) plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma . in december 2014 , preliminary results from this portion of the trial were reported at december 2014 ash annual meeting including that the recommended phase 2 dose of evofosfamide in combination with bortezomib and low-dose dexamethasone was determined to be 340 mg/m 2 . enrollment is ongoing . evofosfamide is also the subject of clinical trials investigating evofosfamide as a monotherapy or evofosfamide in combination with antiangiogenic therapies in a variety of tumor types . in august 2013 , we announced the initiation of a phase 2 clinical trial of evofosfamide as single-agent monotherapy in patients with advanced melanoma ( which we refer to as the 413 trial ) . a phase 1 dose-escalation study of evofosfamide in combination with sunitinib in patients with advanced renal cell carcinoma , or rcc , gastrointestinal stroma tumors , and pancreatic neuroendocrine tumors ( which we refer to as the 410 trial ) established a recommended phase 2 dose of the combination ; additional development opportunities for the investigation of evofosfamide in combination with sunitinib is scheduled to be initiated for the treatment of pancreatic neuroendocrine tumors this year . two investigator-sponsored trials of evofosfamide are ongoing : a phase 1/2 study of evofosfamide in combination with bevacizumab in recurrent glioblastoma following bevacizumab failure and a phase 1/2 study of evofosfamide in combination with sorafenib in advanced rcc and advanced hepatocellular carcinoma . an additional fda-funded phase 2 investigator-sponsored trial of evofosfamide in combination with bevacizumab in recurrent glioblastoma following bevacizumab failure is expected to commence in the first half of 2015. we are working to broaden the potential applicability of evofosfamide as well as to discover additional therapeutics that will selectively target cancer cells . we also seek to optimize patient selectivity for our hypoxia-targeted therapeutics through the development of our [ 18f ] -hx4 investigational hypoxia positron emission tomography ( pet ) tracer . [ 18f ] -hx4 is a radiolabeled tracer that we acquired from siemens healthcare molecular imaging to potentially identify and quantify the degree of hypoxia in tumors in vivo . in september 2014 , we licensed worldwide rights to a development program from the university of auckland based on the clinical-stage oncology compound th-4000 ( formerly referred to as pr610 , or hypoxin ) , a hypoxia-activated epidermal growth factor receptor , or egfr , tyrosine-kinase inhibitor ( tki ) . th-4000 is designed to selectively release a potent , irreversible egfr-tki in hypoxic tumors . preclinical and phase 1 clinical data suggest that plasma concentrations of th-4000 that are active in egfr-dependent tumor xenograft models in mice could be attained in patients with an acceptable therapeutic index . we expect to initiate a phase 2 proof-of-concept study in a subset of molecularly-defined non-small cell lung cancer patients who we believe may be responsive to th-4000 in the first half of 2015. we were incorporated in october 2001. we have devoted substantially all of our resources to research and development of our product candidates . we have not generated any revenue from the commercial sales of our product candidates , and since inception we have funded our operations through the private placement and public offering of equity securities and through payments received under our license and co-development agreement with merck kgaa . as of december 31 , 2014 and december 31 , 2013 , we had cash , cash equivalents and marketable securities of $ 58.6 million and $ 82.0 million , respectively . in february 2015 , we completed an underwritten public offering of 8,300,000 shares of our common stock and accompanying warrants to purchase up to 8,300,000 shares of our common stock . we estimate that the net proceeds from the sale of common stock and accompanying warrants , excluding the proceeds , if any , from the exercise of the warrants issued in the offering , will be approximately $ 28.2 million after deducting the underwriting discount and estimated offering expenses payable by us . for more information on our february 2015 offering , see “ liquidity and capital resources ” below . story_separator_special_tag if adequate funds are not available , we may be required to significantly reduce or refocus our operations or to obtain funds through additional arrangements that may require us to relinquish rights to certain of our products , technologies or potential markets , any of which could delay or require that we curtail or eliminate some or all of our development programs or otherwise have a material adverse effect on our business , financial condition and results of operations . in addition , we may have to delay , reduce the scope of or eliminate some of our research and development , which could delay the time to market for any of our product candidates , if adequate funds are not available . if we are unable to secure additional financing on a timely basis or on terms favorable to us , we may be required to cease or reduce certain research and development projects , to sell some or all of our technology or assets or to merge all or a portion of our business with another entity . insufficient funds may require us to delay , scale back , or eliminate some or all of our activities , and if we are unable to obtain additional funding , there is uncertainty regarding our continued existence . obligations and commitments we lease certain of our facilities under noncancelable leases , which qualify for operating lease accounting treatment under asc 840 , “ leases , ” and , as such , these facilities are not included on our consolidated balance sheets . we entered into a noncancelable facility sublease agreement for 28,650 square feet of laboratory space and office space located in south san francisco , california , which serves as our corporate headquarters . the lease began on october 1 , 2011 and will expire on april 30 , 2017. the aggregate rent for the term of the lease is approximately $ 3.4 million . in addition , the lease requires us to pay certain taxes , assessments , fees and other costs associated with the premises , in amounts yet to be determined . in connection with the execution of the lease we paid a security deposit of approximately $ 60,000. in november 2013 , we entered into a noncancelable facility lease agreement for 7,934 square feet of additional office space located in south san francisco , california . the lease began on december 1 , 2013 and will expire on december 31 , 2016. the aggregate rent for the term of the lease is approximately $ 0.7 million . 60 our major outstanding contractual obligations consist of amounts due under our operating lease agreements and purchase commitments under contract research , development and clinical supply agreements . contractual obligations and related scheduled payments as of december 31 , 2014 are as follows ( in thousands ) : replace_table_token_7_th we have not included milestone or royalty payments or other contractual payment obligations in the table above if the amount and timing of such obligations are unknown or uncertain . at the market stock issuance facilities on october 29 , 2010 , we entered into an at market issuance sales agreement , as amended , or the prior sales agreement , with mlv , pursuant to which we were able to issue and sell shares of our common stock having an aggregate offering price of up to $ 17.6 million from time to time through mlv as our sales agent . we paid mlv an aggregate commission rate of 3.0 % of the gross proceeds of the sales price per share of the common stock sold under the prior sales agreement . during year ended december 31 , 2012 , we sold 2,022,144 shares of our common stock at an average price of $ 6.29 pursuant to the prior sales agreement . net proceeds from the sale of the common stock in 2012 were $ 12.3 million . in 2013 and 2014 , no shares were sold pursuant to the prior sales agreement . in april 2014 , the prior sales agreement was terminated . on august 1 , 2014 , we entered into a new at market issuance sales agreement , or the current sales agreement , with mlv , which provides that , upon the terms and subject to the conditions and limitations set forth in the current sales agreement , we may elect to issue and sell shares of our common stock having an aggregate offering price of up to $ 30.0 million from time to time through mlv as our sales agent . sales of our common stock through mlv , if any , will be made on the nasdaq capital market by means of ordinary brokers ' transactions at market prices , in block transactions or as otherwise agreed by us and mlv . subject to the terms and conditions of the current sales agreement , mlv will use commercially reasonable efforts to sell our common stock from time to time , based upon our instructions ( including any price , time or size limits or other customary parameters or conditions we may impose ) . we are not obligated to make any sales of common stock under the current sales agreement . we will pay mlv an aggregate commission rate of up to 3.0 % of the gross proceeds of the sales price per share of any common stock sold under the current sales agreement . the number of shares we are able to sell under this arrangement will be limited in practice based on the trading volume of our common stock . we have not yet sold any common stock pursuant to the current sales agreement . following the adjustment date with respect to the warrants issued in our 2015 public offering , sales of the stock under the current sales agreement could result in a downward adjustment to the exercise price of those warrants . license and development agreements on september

liquidity and capital resources we have not generated and do not expect to generate revenue from sales of our product candidates in the near term . since our inception , we have funded our operations primarily through private placements and public offerings of equity securities and through payments received under our license and co-development agreement with merck kgaa . during the year ended december 31 , 2014 , we received approximately $ 4.8 million from the exercise of warrants to purchase approximately 2.3 million shares of common stock . during the year ended december 31 , 2013 , we received approximately $ 1.9 million from the exercise of warrants to purchase approximately 2.4 million shares of common stock . during the year ended december 31 , 2012 , we sold an aggregate of approximately 2.0 million shares of common stock under our prior at market issuance sales agreement with mlv & co. , llc , or mlv , for net proceeds of $ 12.3 million , and we received approximately $ 8.8 million from the exercise of warrants to purchase approximately 4.7 million shares of common stock . to date we have received upfront and milestone payments of $ 110 million under our license and co-development agreement with merck kgaa . we had cash , cash equivalents and marketable securities of $ 58.6 million and $ 82.0 million at december 31 , 2014 and december 31 , 2013 , respectively , available to fund operations . in february 2015 , we completed an underwritten public offering of 8,300,000 shares of our common stock and accompanying warrants to purchase up to 8,300,000 shares of our common stock . we estimate that the net proceeds from the sale of common stock and accompanying warrants , excluding the proceeds , if any , from the exercise of the warrants issued in the offering , will be approximately $ 28.2 million after deducting the underwriting discount and estimated offering expenses payable by us .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources we have not generated and do not expect to generate revenue from sales of our product candidates in the near term . since our inception , we have funded our operations primarily through private placements and public offerings of equity securities and through payments received under our license and co-development agreement with merck kgaa . during the year ended december 31 , 2014 , we received approximately $ 4.8 million from the exercise of warrants to purchase approximately 2.3 million shares of common stock . during the year ended december 31 , 2013 , we received approximately $ 1.9 million from the exercise of warrants to purchase approximately 2.4 million shares of common stock . during the year ended december 31 , 2012 , we sold an aggregate of approximately 2.0 million shares of common stock under our prior at market issuance sales agreement with mlv & co. , llc , or mlv , for net proceeds of $ 12.3 million , and we received approximately $ 8.8 million from the exercise of warrants to purchase approximately 4.7 million shares of common stock . to date we have received upfront and milestone payments of $ 110 million under our license and co-development agreement with merck kgaa . we had cash , cash equivalents and marketable securities of $ 58.6 million and $ 82.0 million at december 31 , 2014 and december 31 , 2013 , respectively , available to fund operations . in february 2015 , we completed an underwritten public offering of 8,300,000 shares of our common stock and accompanying warrants to purchase up to 8,300,000 shares of our common stock . we estimate that the net proceeds from the sale of common stock and accompanying warrants , excluding the proceeds , if any , from the exercise of the warrants issued in the offering , will be approximately $ 28.2 million after deducting the underwriting discount and estimated offering expenses payable by us .
```    
 Suspicious Activity Report : in march 2014 , we announced that merck kgaa initiated a phase 1 dose escalation study assessing the safety , tolerability and anti-tumor activity of evofosfamide in combination with gemcitabine and nab-paclitaxel ( abraxane ® ) in patients with previously untreated , locally advanced unresectable or metastatic pancreatic adenocarcinoma . in june 2014 , we announced the initiation of a 440-patient , randomized , double-blind , placebo-controlled trial of evofosfamide in combination with pemetrexed in patients with second-line advanced non-squamous non-small cell lung cancer ( which we refer to as the 415 trial ) . the international phase 2 trial is designed to support registration and will compare the combination of evofosfamide plus pemetrexed versus the combination of pemetrexed plus placebo as second-line therapy in this patient population . the study 's primary efficacy endpoint is overall survival and secondary endpoints include safety and assessment of anti-tumor activity as determined by progression-free survival and objective response rate . 54 in march 2012 , we initiated a phase 1/2 open label clinical trial of evofosfamide to determine the maximum tolerated dose , dose limiting toxicity , safety , tolerability , clinical activity , and pharmacokinetics of evofosfamide in patients with relapsed/refractory multiple myeloma ( which we refer to as the 408 trial ) . updated results were reported at the june 2014 asco annual meeting showing initial signs of clinical activity of the combination of evofosfamide and low dose dexamethasone in patients with extensively treated relapsed/refractory multiple myeloma . in july 2014 , we announced the initiation of dosing in the final stage of the 408 trial , which is evaluating evofosfamide in combination with the proteasome inhibitor bortezomib ( velcade ® ) plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma . in december 2014 , preliminary results from this portion of the trial were reported at december 2014 ash annual meeting including that the recommended phase 2 dose of evofosfamide in combination with bortezomib and low-dose dexamethasone was determined to be 340 mg/m 2 . enrollment is ongoing . evofosfamide is also the subject of clinical trials investigating evofosfamide as a monotherapy or evofosfamide in combination with antiangiogenic therapies in a variety of tumor types . in august 2013 , we announced the initiation of a phase 2 clinical trial of evofosfamide as single-agent monotherapy in patients with advanced melanoma ( which we refer to as the 413 trial ) . a phase 1 dose-escalation study of evofosfamide in combination with sunitinib in patients with advanced renal cell carcinoma , or rcc , gastrointestinal stroma tumors , and pancreatic neuroendocrine tumors ( which we refer to as the 410 trial ) established a recommended phase 2 dose of the combination ; additional development opportunities for the investigation of evofosfamide in combination with sunitinib is scheduled to be initiated for the treatment of pancreatic neuroendocrine tumors this year . two investigator-sponsored trials of evofosfamide are ongoing : a phase 1/2 study of evofosfamide in combination with bevacizumab in recurrent glioblastoma following bevacizumab failure and a phase 1/2 study of evofosfamide in combination with sorafenib in advanced rcc and advanced hepatocellular carcinoma . an additional fda-funded phase 2 investigator-sponsored trial of evofosfamide in combination with bevacizumab in recurrent glioblastoma following bevacizumab failure is expected to commence in the first half of 2015. we are working to broaden the potential applicability of evofosfamide as well as to discover additional therapeutics that will selectively target cancer cells . we also seek to optimize patient selectivity for our hypoxia-targeted therapeutics through the development of our [ 18f ] -hx4 investigational hypoxia positron emission tomography ( pet ) tracer . [ 18f ] -hx4 is a radiolabeled tracer that we acquired from siemens healthcare molecular imaging to potentially identify and quantify the degree of hypoxia in tumors in vivo . in september 2014 , we licensed worldwide rights to a development program from the university of auckland based on the clinical-stage oncology compound th-4000 ( formerly referred to as pr610 , or hypoxin ) , a hypoxia-activated epidermal growth factor receptor , or egfr , tyrosine-kinase inhibitor ( tki ) . th-4000 is designed to selectively release a potent , irreversible egfr-tki in hypoxic tumors . preclinical and phase 1 clinical data suggest that plasma concentrations of th-4000 that are active in egfr-dependent tumor xenograft models in mice could be attained in patients with an acceptable therapeutic index . we expect to initiate a phase 2 proof-of-concept study in a subset of molecularly-defined non-small cell lung cancer patients who we believe may be responsive to th-4000 in the first half of 2015. we were incorporated in october 2001. we have devoted substantially all of our resources to research and development of our product candidates . we have not generated any revenue from the commercial sales of our product candidates , and since inception we have funded our operations through the private placement and public offering of equity securities and through payments received under our license and co-development agreement with merck kgaa . as of december 31 , 2014 and december 31 , 2013 , we had cash , cash equivalents and marketable securities of $ 58.6 million and $ 82.0 million , respectively . in february 2015 , we completed an underwritten public offering of 8,300,000 shares of our common stock and accompanying warrants to purchase up to 8,300,000 shares of our common stock . we estimate that the net proceeds from the sale of common stock and accompanying warrants , excluding the proceeds , if any , from the exercise of the warrants issued in the offering , will be approximately $ 28.2 million after deducting the underwriting discount and estimated offering expenses payable by us . for more information on our february 2015 offering , see “ liquidity and capital resources ” below . story_separator_special_tag if adequate funds are not available , we may be required to significantly reduce or refocus our operations or to obtain funds through additional arrangements that may require us to relinquish rights to certain of our products , technologies or potential markets , any of which could delay or require that we curtail or eliminate some or all of our development programs or otherwise have a material adverse effect on our business , financial condition and results of operations . in addition , we may have to delay , reduce the scope of or eliminate some of our research and development , which could delay the time to market for any of our product candidates , if adequate funds are not available . if we are unable to secure additional financing on a timely basis or on terms favorable to us , we may be required to cease or reduce certain research and development projects , to sell some or all of our technology or assets or to merge all or a portion of our business with another entity . insufficient funds may require us to delay , scale back , or eliminate some or all of our activities , and if we are unable to obtain additional funding , there is uncertainty regarding our continued existence . obligations and commitments we lease certain of our facilities under noncancelable leases , which qualify for operating lease accounting treatment under asc 840 , “ leases , ” and , as such , these facilities are not included on our consolidated balance sheets . we entered into a noncancelable facility sublease agreement for 28,650 square feet of laboratory space and office space located in south san francisco , california , which serves as our corporate headquarters . the lease began on october 1 , 2011 and will expire on april 30 , 2017. the aggregate rent for the term of the lease is approximately $ 3.4 million . in addition , the lease requires us to pay certain taxes , assessments , fees and other costs associated with the premises , in amounts yet to be determined . in connection with the execution of the lease we paid a security deposit of approximately $ 60,000. in november 2013 , we entered into a noncancelable facility lease agreement for 7,934 square feet of additional office space located in south san francisco , california . the lease began on december 1 , 2013 and will expire on december 31 , 2016. the aggregate rent for the term of the lease is approximately $ 0.7 million . 60 our major outstanding contractual obligations consist of amounts due under our operating lease agreements and purchase commitments under contract research , development and clinical supply agreements . contractual obligations and related scheduled payments as of december 31 , 2014 are as follows ( in thousands ) : replace_table_token_7_th we have not included milestone or royalty payments or other contractual payment obligations in the table above if the amount and timing of such obligations are unknown or uncertain . at the market stock issuance facilities on october 29 , 2010 , we entered into an at market issuance sales agreement , as amended , or the prior sales agreement , with mlv , pursuant to which we were able to issue and sell shares of our common stock having an aggregate offering price of up to $ 17.6 million from time to time through mlv as our sales agent . we paid mlv an aggregate commission rate of 3.0 % of the gross proceeds of the sales price per share of the common stock sold under the prior sales agreement . during year ended december 31 , 2012 , we sold 2,022,144 shares of our common stock at an average price of $ 6.29 pursuant to the prior sales agreement . net proceeds from the sale of the common stock in 2012 were $ 12.3 million . in 2013 and 2014 , no shares were sold pursuant to the prior sales agreement . in april 2014 , the prior sales agreement was terminated . on august 1 , 2014 , we entered into a new at market issuance sales agreement , or the current sales agreement , with mlv , which provides that , upon the terms and subject to the conditions and limitations set forth in the current sales agreement , we may elect to issue and sell shares of our common stock having an aggregate offering price of up to $ 30.0 million from time to time through mlv as our sales agent . sales of our common stock through mlv , if any , will be made on the nasdaq capital market by means of ordinary brokers ' transactions at market prices , in block transactions or as otherwise agreed by us and mlv . subject to the terms and conditions of the current sales agreement , mlv will use commercially reasonable efforts to sell our common stock from time to time , based upon our instructions ( including any price , time or size limits or other customary parameters or conditions we may impose ) . we are not obligated to make any sales of common stock under the current sales agreement . we will pay mlv an aggregate commission rate of up to 3.0 % of the gross proceeds of the sales price per share of any common stock sold under the current sales agreement . the number of shares we are able to sell under this arrangement will be limited in practice based on the trading volume of our common stock . we have not yet sold any common stock pursuant to the current sales agreement . following the adjustment date with respect to the warrants issued in our 2015 public offering , sales of the stock under the current sales agreement could result in a downward adjustment to the exercise price of those warrants . license and development agreements on september

